Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

COVID-19 GPH|Home|PHGKB Last data update: May 28, 2022 . (Total: 35919 Documents since 2020)

Last Posted: May-28-2022 11:50:13
spot light Spotlight

COVID-19 in 2022-The Beginning of the End or the End of the Beginning?
Del Rio Carlos et al. JAMA 2022 5

While many questions remain about the future of the pandemic, it is clear that SARS-CoV-2 will not be fully eradicated. This means continuing to adapt to life with COVID-19 and recognizing that during the next phase of the pandemic, there will be times when community transmission will be low and precautions can be “dialed down” and times when increased transmission will require mitigation efforts to be “dialed up.”

Why call it BA.2.12.1? A guide to the tangled Omicron family
A Maxmen, Nature, May 27, 2022

We explores how subvariants are named, and why none of Omicron’s family members has been upgraded to a ‘variant of concern’. “We want to name everything that jumps out at us at an early stage so that we can define it and track it, and see if it is growing quickly relative to other lineages,” says Andrew Rambaut, an evolutionary biologist at the University of Edinburgh and a member of Pango. “You probably won’t hear of most of the lineages we name,” he says, because they couldn’t compete with other versions of SARS-CoV-2 and have disappeared.

Host genetic basis of COVID-19: from methodologies to genes
K Zguro et al, EJHG, May 27, 2022

This review delineates GWAS and Burden test as traditional methodologies employed so far for the discovery of the human genetic basis of COVID-19, with particular attention to recently emerged predictive models such as the post-Mendelian model. A summary table with the main genome-wide significant genomic loci is provided. Besides, various common and rare variants identified in genes like TLR7, CFTR, ACE2, TMPRSS2, TLR3, and SELP are further described in detail to illustrate their association with disease severity.

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron
NEJM, May 25, 2022

Our results show that all the regimens that included a booster dose, as compared with no vaccination, offered protection against symptomatic omicron infection (the 95% confidence intervals did not include 0), although vaccine effectiveness was highest for the regimens that included a booster dose of an mRNA vaccine and was lowest for the homologous Ad26.COV2.S/Ad26.COV2.S regimen. The vaccine effectiveness of the three-dose mRNA regimen and the Ad26.COV2.S/mRNA regimen was lower during the period of 2 to 4 months since receipt of the booster dose than during the period of 14 days to 1 month since receipt of the booster dose.

About COVID-19 GPH

COVID-19 GPH is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that capture emerging discoveries and applications of genomics, molecular and other precision medicine and precision public health tools in the investigation and control of COVID-19. Contents include PubMed records via an automated pubmed search algorithm, preprint records from NIH iCite, the relevant information from many media sources picked by experts, and linkages to contents from our curated PHGKB databases.
update trend

Sign up Email Alert


All Records35919
Genomics Precision Health25961
Non-Genomics Precision Health9958

Publication Categories Brand

Variants 8820
Vaccines 8010
Mechanism 7704
Treatment 7341
Diagnosis 5289
Prevention 4236
Surveillance 3048
Forecasting 2791
Transmission 1628
Health Equity 917

Publication Types

PubMed Records26388
Online News/Reports/Publications431

Genomics Precision Health (GPH): The use of pathogen and human genomics and advanced molecular detection methods in discovery, clinical and public health investigations and response to COVID-19.
Non Genomics Precision Health (non-GPH): The use of big data, data science, digital health, machine learning and predictive analytic methods (not involving genomics) in discovery, clinical and public health investigations and response to COVID-19

Following categories are annotated by LitCovid from NCBI NIH.
MechanismUnderlying cause(s) of covid-19 infections and transmission & possible drug mechanism of action
Transmission Characteristics and modes of covid-19 transmissions, such as human-to-human
DiagnosisDisease assessment through symptoms, test results, and radiological features
PreventionPrevention, control, response and management strategies
Case ReportDescriptions of specific patient cases
ForecastingModelling and estimating the trend of covid-19 spread

Following categories are annotated by the text mining tool from CDC PHGKB
Health EquityRelevant to health equity. Search terms are derived from a list provided by the Association for Territorial Health Officials which include terms such as diversity, health disparities, and others.
VaccineRelevant to vaccine development, evaluation, implementation and impact. For additional information on vaccines and COVID-19. Check out general CDC Information pages
VariantRelevant to SARS-CoV-2 variants and their impact on public health. For additional information on variants COVID-19. Check out CDC New Variants of the Virus that Causes COVID-19 page
SurveillanceRelevant to SARS-CoV-2 public health surveillance and tracking. For additional information on COVID-19 surveillance, check out CDC COVID-19 Data Tracker

Disclaimer: Articles listed in the Public Health Genomics and Precision Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.